chronic graft-versus-host-disease (cGVHD)

April 16, 2018

Blocking a MicroRNA Improves Symptoms of Chronic Graft-versus-Host Disease in Mouse Model

News

Blocking a specific microRNA molecule reduced symptoms of graft-versus-host disease (GVHD) in mouse models of bone marrow transplants, a study shows. Findings from this research, led by investigators at the ... Read more

October 31, 2017

Health Canada OKs Imbruvica for Treating Chronic Graft-Versus-Host Disease

News

Janssen‘s Imbruvica (ibrutinib) has been approved by Health Canada for treating chronic graft-versus-host disease (cGVHD), a life-threatening condition that some patients develop after a stem cell transplant. Following a priority ... Read more

August 4, 2017August 4, 2017

FDA Approves Imbruvica for Adults with Chronic Graft-Versus-Host-Disease

News

The U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for patients with chronic graft-versus-host-disease (cGVHD) who failed to respond to other lines of therapy. With this decision, Imbruvica, already approved for ... Read more